ALSUntangled #68: ozone therapy

Yuyao Sun; Paul Barkhaus; Benjamin Barnes; Morgan Beauchamp; Michael Benatar; Tulio Bertorini; Mark Bromberg; Gregory T Carter; Jesse Crayle; Merit Cudkowicz; Mazen Dimachkie; Eva L Feldman; Timothy Fullam; Terry Heiman-Patterson; Sartaj Jhooty; Isaac Lund; Christopher Mcdermott; Gary Pattee; Kaitlyn Pierce; Dylan Ratner; Paul Wicks; Richard Bedlack

doi:10.1080/21678421.2022.2145904

ALSUntangled #68: ozone therapy

Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):548-552. doi: 10.1080/21678421.2022.2145904. Epub 2022 Nov 18.

Authors

Yuyao Sun¹, Paul Barkhaus², Benjamin Barnes³, Morgan Beauchamp⁴, Michael Benatar⁵, Tulio Bertorini⁶, Mark Bromberg⁷, Gregory T Carter⁸, Jesse Crayle⁹, Merit Cudkowicz¹⁰, Mazen Dimachkie¹¹, Eva L Feldman¹², Timothy Fullam¹³, Terry Heiman-Patterson¹⁴, Sartaj Jhooty¹⁵, Isaac Lund¹⁶, Christopher Mcdermott¹⁷, Gary Pattee¹⁸, Kaitlyn Pierce¹⁹, Dylan Ratner²⁰, Paul Wicks²¹, Richard Bedlack²²

Affiliations

¹ Neurology Department, University of Kentucky, Lexington, KY, USA.
² Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.
³ Department of Neurology, Medical College of Georgia, Augusta, GA, USA.
⁴ Neurosciences Clinical Trials Unit, UNC Chapel Hill NC, Chapel Hill, NC, USA.
⁵ Department of Neurology, University of Miami, Miami, FL, USA.
⁶ Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA.
⁷ Department of Neurology, University of Utah, Salt Lake City, UT, USA.
⁸ Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
⁹ Neurology Department, Washington University, St. Louis, MO, USA.
¹⁰ Department of Neurology, Harvard Medical School, Boston, MA, USA.
¹¹ Department of Neurology, University of Kansas, Kansas City, KS, USA.
¹² Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
¹³ Department of Neurology, UTSA, San Antonio, TX, USA.
¹⁴ Department of Neurology, Temple Health, Philadelphia, PA, USA.
¹⁵ Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹⁶ Green Hope High School, Cary, NC, USA.
¹⁷ Department of Neuroscience, University of Sheffield, Sheffield, UK.
¹⁸ Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.
¹⁹ Department of Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
²⁰ Longmeadow High School, Longmeadow, MA, USA.
²¹ Independent Consultant, Lichfield, UK.
²² Department of Neurology, Duke University, Durham, NC, USA.

PMID: 36398749
DOI: 10.1080/21678421.2022.2145904

Abstract

ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review ozone therapy. Ozone therapy has possible mechanisms for slowing ALS progression based on its antioxidant, anti-inflammatory, and mitochondrial effects. A non-peer-reviewed report suggests that ozone treatment may slow progression in a mTDP-43 mouse model of ALS. One verified "ALS reversal" occurred on a cocktail of alternative treatments including ozone. There are no ALS trials using ozone to treat PALS. There can be potentially serious side effects associated with ozone therapy, depending on the dose. Based on the above information, we support an investigation of ozone therapy in ALS cell or animal models but cannot yet recommend it as a treatment in PALS.

Keywords: ALS; alternative therapy; neurodegeneration; oxidative stress; ozone therapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Amyotrophic Lateral Sclerosis* / drug therapy
Animals
Disease Models, Animal
Humans
Mice
Mitochondria